Status:
UNKNOWN
Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)
Lead Sponsor:
Direction Centrale du Service de Santé des Armées
Conditions:
Respiratory Tract Infections
Respiratory Tract Disease
Eligibility:
All Genders
18+ years
Brief Summary
The SARS-CoV2 virus causes severe or even fatal disease in a fraction of infected people. The clinical severity is based on a complicated pneumopathy with acute respiratory distress syndrome that can ...
Eligibility Criteria
Inclusion
- Patient admitted to intensive care unit with confirmed SARS-CoV2 infection
- Patient older than 18 years old
Exclusion
- Patient coming from another intensive care unit after more than 5 days in the intensive care unit
- Known immunosuppression:
- Known or suspected HIV
- Known or suspected immunosuppression :
- Organ transplantation
- Marrow transplant
- Congenital deficit
- Received immunosuppressive therapy within 30 days (azathioprine, methotrexate, tacrolimus, cyclosporine, sirolimus, cyclophosphamide, rituximab, anti-TNF, JAK inhibitors, corticosteroids \>10mg/day over the last 30 days, recent covid-19 corticosteroid therapy \>1mg/kg prednisolone or equivalent \>5 days)
- Administration of chemotherapy within the last 3 months
- Current pregnancy or breastfeeding
- Patient under 18 years of age
- Incapacitated adults and persons deprived of their liberty
- Refusal by the patient or his/her support person
Key Trial Info
Start Date :
April 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 21 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04365166
Start Date
April 21 2020
End Date
April 21 2022
Last Update
March 9 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Percy Military Teaching Hospital
Clamart, France, 92140
2
Bégin Military Teaching Hospital
Saint-Mandé, France, 94163